Method of cancer screening; method of cancer treatment; and method of diabetes treatment

Abstract

A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood tumor cell count. If all of the foregoing steps are positive, the cancer is treated by applying imiquimod transdermally to rotating sites, preferably by mixing ALDARA® (imiquimod) 5% cream with an equal amount of H base cream; administering a vaccine containing tumor necrosis factor, preferably the BCG vaccine; and orally administering VALTREX® (valacyclovir) twice daily. The foregoing treatment method is also effective in treating Type I diabetes, MS, and other epidermal cancers.

1 . A method of cancer screening and cancer treatment comprising the steps of: 
 administering the Blood CA 27,29 testing procedure and thereby determining the presence of a predetermined cancer; and    the subsequent step of treating the cancer identified by the preceding step by concurrent transdermal administration of imiquimod, injection of a vaccine containing tumor necrosis factor, and oral administration of valacyclovir.    
     
     
         2 . The method of cancer screening according to  claim 1  wherein the step transdermally administering imiquimod is carried out by mixing ¼ cc of ALDARA®(imiquimod) 5% cream with ¼ cc H base cream (i) and transdermally administering the resulting mixture.  
     
     
         3 . A method of treating duct cell breast cancer comprising the steps of: 
 providing a quantity of ALDARA™ 5% cream;    providing a quantity of H base cream™;    mixing ¼ cc. of the ALDARA™ 5% cream with ¼ cc. of the H base cream™ and transdermally administering the resulting mixture to the patient;    administering a vaccine containing tumor necrosis factor; and    orally administering Valtrex™ tablets.    
     
     
         4 . The method of treating duct cell breast cancer according to  claim 3  wherein the ALDARA™ 5% creamtH base cream mixture is applied daily and the progress of the procedure is monitored using the Blood CA 27,29 testing procedure.  
     
     
         5 . The method of treating duct cell breast cancer according to  claim 3  wherein the vaccine containing tumor necrosis factor is administered every three weeks and 500 mg Valtrex™ tablets are orally administered twice daily.  
     
     
         6 . The method of treating duct cell breast cancer according to  claim 5  wherein the progress of the procedure is monitored using the Blood CA 27,29 testing procedure.  
     
     
         7 . A method of treating Type I diabetes comprising the steps of: 
 providing a quantity of ALDARA™ 5% cream;    providing a quantity of H base cream™;    mixing ¼ cc. of the ALDARA™ 5% cream with ¼ cc. of the H base cream™ and transdermally administering the resulting mixture to the patient;    administering a vaccine containing tumor necrosis factor; and    orally administering Valtrex™ tablets.    
     
     
         8 . The method of treating Type I diabetes according to  claim 7  wherein the ALDARA™ 5% cream/H base cream mixture is applied daily, the vaccine containing tumor necrosis factor is administered every three weeks and 500 mg Valtrex GM) tablets are orally administered twice daily.  
     
     
         9 . A method of treating multiple sclerosis comprising the steps of: 
 providing a quantity of ALDARA™ 5% cream;    providing a quantity of H base cream™;    mixing ¼ cc. of the ALDARA™ 5% cream with ¼ cc. of the H base cream™ and transdermally administering the resulting mixture to the patient;    administering a vaccine containing tumor necrosis factor; and    orally administering Valtrex™ tablets.    
     
     
         10 . The method of treating multiple sclerosis according to  claim 9  wherein the ALDARA™ 5% cream/H base cream mixture is applied daily, the vaccine containing tumor necrosis factor is administered every three weeks and 500 mg Valtrex™ tablets are orally administered twice daily.